Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free NVO Stock Alerts

Novo Nordisk A/S (NVO) News Today

Novo Nordisk A/S logo
$38.62 +0.44 (+1.16%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$38.60 -0.03 (-0.08%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Novo Nordisk A/S Latest News

Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land
October 9 at 10:06 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-081210591.html
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
October 9 at 10:06 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-nvo-raised-outlook-132822998.html
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
October 8 at 10:15 PM  |  fool.comhttps://www.fool.com/investing/2026/10/08/ubs-called-novo-nordisk-a-value-trap-heres-the-oth/
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’
October 8 at 7:07 PM  |  barchart.comhttps://www.barchart.com/story/news/5091202/novo-nordisks-ceo-was-asked-why-his-stock-keeps-falling-on-good-news-the-stock-market-is-always-right-but-with-a-bit-of-a-time-difference
Novo Nordisk Wraps Up Real World Joint Health Study for Esperoct in Haemophilia A
October 8 at 12:30 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/novo-nordisk-wraps-up-real-world-joint-health-study-for-esperoct-in-haemophilia-a?utm_source=marketbeat.com&utm_medium=referral
A declining-to-rising stock chart graphic, and text reading "Buy the Dip" and "Now".
Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)
Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.
October 8 at 9:55 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/only-20-stocks-are-holding-up-the-market-3-bargains-outside-ai/
Head-To-Head Contrast: Tarsus Pharmaceuticals (NASDAQ:TARS) versus Novo Nordisk A/S (NYSE:NVO)
October 8 at 4:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098950
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-nvo-increases-despite-204505225.html
Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-cpse-novo-b-130956416.html
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
October 6, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/06/novo-stock-is-down-more-than-70-from-its-peak-valu/
Novo Nordisk A/S $NVO Stock Sold by Eastern Bank
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novo-nordisk-as-nvo-stock-sold-by-eastern-bank-2026-10-06/
Novo Looks Beyond GLP-1s as Competition Intensifies
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-looks-beyond-glp-1s-125437665.html
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cn-bio-announces-expert-speaker-161200005.html
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/type-2-diabetes-market-grow-170000037.html
Novo Looks Beyond GLP-1s as Competition Intensifies
October 5, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/novo-looks-beyond-glp-1s-as-competition-intensifies-1844257/
Novo Nordisk A/S – Share repurchase programme
October 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-share-repurchase-programme-123200929.html
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
October 4, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/04/better-high-yield-dividend-stock-pfizer-or-novo-no/
LENZ Therapeutics (NASDAQ:LENZ) and Novo Nordisk A/S (NYSE:NVO) Head to Head Review
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084392
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
October 3, 2026  |  rttnews.comhttps://www.rttnews.com/3696255/novo-nordisk-plans-denecimib-u-s-launch-in-h1-2027-amid-fda-review-extension.aspx
Novo Nordisk A/S: Novo provides update on the denecimig Biologics License Application (BLA) in the US
October 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69745564-novo-nordisk-a-s-novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us-399.htm
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
October 2, 2026  |  fool.comhttps://www.fool.com/investing/2026/10/02/novo-nordisk-strikes-nearly-usd4-billion-in-2-deals-here-s-what-that-means-for-investors/
Novo provides update on the denecimig Biologics License Application (BLA) in the US
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-provides-denecimig-biologics-license-205300531.html
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
October 2, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/us-fda-extends-review-novo-nordisks-hemophilia-drug-over-facility-issues-2026-10-02/
Novo provides update on the denecimig Biologics License Application (BLA) in the US
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
October 2, 2026  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/02/novo-nordisk-vs-pfizer-which-healthcare-stock-is-a-better-buy-in-2026/
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
October 2, 2026  |  cnbc.comhttps://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html
Eli Lilly obesity drug data adds pressure on Novo Nordisk
October 2, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099453/eli-lilly-obesity-drug-data-adds-pressure-on-novo-nordisk-1099453.html
Eli Lilly obesity drug data adds pressure on Novo Nordisk
October 2, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099453?snapi
Novo Nordisk A/S's (NVO) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076444
Novo Nordisk Reports Post Hoc Data For Wegovy Showing Effective Liver Fat Control
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695893/novo-nordisk-reports-post-hoc-data-for-wegovy-showing-effective-liver-fat-control.aspx
Novo's Wegovy Shows Liver Fat Falling Into Normal Range In 72 Weeks
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695898/novo-s-wegovy-shows-liver-fat-falling-into-normal-range-in-72-weeks.aspx
Novo Nordisk's Wegovy Reduces Liver Fat In Obesity Without Diabetes
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695882/novo-nordisk-s-wegovy-reduces-liver-fat-in-obesity-without-diabetes.aspx
Novo Nordisk's Wegovy normalized liver fat in nine out of 10 patients in analysis
October 1, 2026  |  marketscreener.comM
If You Love Speculating, You Should Keep a Close Eye on Novo Nordisk Stock
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/love-speculating-keep-close-eye-140320112.html
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-wegovy-semaglutide-reduced-liver-104500643.html
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
September 30, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/30/novo-is-open-to-acquisitions-here-are-2-companies/
Novo Nordisk CagriSema Cuts "Food Noise", Shows Organ And Bone Health Benefits
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695434/novo-nordisk-cagrisema-cuts-food-noise-shows-organ-and-bone-health-benefits.aspx
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
September 30, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/30/could-this-company-challenge-eli-lilly-and-novo-nordisk-in-the-weight-loss-market/
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
September 30, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/09/62087246/novo-nordisk-says-next-gen-obesity-drug-reduces-food-noise-drives-weight-loss?utm_source=snapi
Novo Nordisk A/S's (NVO) "Sell" Rating Reiterated at Deutsche Bank Aktiengesellschaft
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-novo-nordisk-ass-nvo-sell-rating-reiterated-at-deutsche-bank-aktiengesellschaft-2026-09-30/
Novo Nordisk: The Street Sold It For The Wrong Reason
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951035-novo-nordisk-the-street-sold-it-for-the-wrong-reason
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
September 30, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
September 30, 2026  |  cnbc.comhttps://www.cnbc.com/2026/09/30/novo-wegovy-pill-weight-loss-injections.html
Novo Nordisk A/S (NYSE:NVO) Stock Rated "Hold" by Sell-Side Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067939
Novo Nordisk Gives Uninspiring Outlook
September 29, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/29/novo-nordisk-gives-uninspiring-outlook/
Novo Nordisk And Hengrui Pharma Sign Deal Worth Up To $2.6 Bln For Oral GLP-1/GIP Drug
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694658/novo-nordisk-and-hengrui-pharma-sign-deal-worth-up-to-2-6-bln-for-oral-glp-1-gip-drug.aspx
Novo Nordisk: After A 70+% Drop, It's A Great Investment
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950687-novo-nordisk-after-a-70-plus-percent-drop-its-a-great-investment
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-190535170.html
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-delivers-fresh-challenge-155737147.html
Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novos-ozempic-semaglutide-2-mg-100000518.html

Novo Nordisk A/S Media Mentions By Week

Novo Nordisk A/S Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NVO
News Sentiment
▼
0.46

0.66
▲
Average
Healthcare
News Sentiment

Novo Nordisk A/S News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NVO Articles
This Week
▼
18

7
▲
NVO Articles
Average Week

Novo Nordisk A/S Trends on MarketBeat

This week vs. last week
New Followers
4
+300%
Searches
18
+157%
Page Views
14,230
-15%
Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Novo Nordisk A/S dated 10/9/2026.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel